13F Holdings
中文EN

IMRN Immuron Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1660046 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY48.6%
TTM net income YoY24.8%
TTM EPS YoY25.7%
Revenue 3-yr CAGR112.0%
Net income 3-yr CAGR—

Margins

Gross margin65.4%
Operating margin-73.3%
Net margin-71.6%
FCF margin—
EBITDA margin-72.7%

Returns

ROE-50.2%
ROA-40.6%
ROIC (approx.)-134.2%
Asset turnover0.57x

Leverage & solvency

Liabilities / assets20.3%
Debt / equity0.00x
Current ratio5.09x
Interest coverage-731.63x

Cash quality & payout

Operating cash flow / net income1.18x
Accruals ratio7.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: AUD FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30
Income statement
Revenue7.29M4.90M1.80M765,193145,776
Cost of revenue2.52M1.57M495,558241,69151,071
Gross profit4.77M3.34M1.31M523,50294,705
R&D expense3.60M5.38M2.59M657,7151.37M
SG&A expense4.48M4.56M4.22M3.52M6.09M
Operating income-5.34M-5.80M-3.57M-2.87M-8.38M
Interest expense7,3057,5769,6526,18413,761
Pretax income-5.22M-6.94M-3.79M-2.85M-8.38M
Net income-5.22M-6.94M-3.79M-2.85M-8.38M
EBITDA-5.29M-5.76M-3.52M-2.84M-8.34M
EPS (basic)-2.26-3.04-1.66-1.25-3.79
EPS (diluted)-2.26-3.04-1.66-1.25-3.79
Weighted avg. shares (diluted)230.94M227.86M227.80M227.58M—
Balance sheet
Cash & equivalents2.83M11.66M17.16M22.11M25.05M
Short-term investments——404,117——
Receivables1.93M1.39M417,420662,896334,707
Inventory1.77M1.58M839,968326,578292,532
Current assets10.02M14.73M20.41M23.67M25.75M
PP&E, netmay include right-of-use assets (IFRS)113,950154,347200,133226,73633,741
Total assets10.13M15.55M21.99M24.86M27.05M
Current liabilities1.97M2.70M2.22M1.50M1.12M
Total liabilities2.06M2.84M2.37M1.68M1.16M
Shareholders' equity8.07M12.71M19.62M23.18M25.90M
Shares outstanding——18——
Cash flow statement
Operating cash flow-6.14M-5.88M-2.60M-3.15M-4.08M
Capital expenditure—1957,73910,0486,630
Free cash flow—-5.88M-2.60M-3.16M-4.09M
Investing cash flow-2.90M327,561-2.62M11,7372,574
Financing cash flow199,747829-44,667-42,44826.48M
Depreciation & amortization49,68845,98148,66226,61343,662
Stock-based compensation304,2433,299226,95494,890—

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.